Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis

Anna Powell; Khalil G Ghanem; Linda Rogers; Ashley Zinalabedini; Rebecca M Brotman; Jonathan Zenilman; Susan Tuddenham

doi:10.1097/OLQ.0000000000001063

Clinicians' Use of Intravaginal Boric Acid Maintenance Therapy for Recurrent Vulvovaginal Candidiasis and Bacterial Vaginosis

Sex Transm Dis. 2019 Dec;46(12):810-812. doi: 10.1097/OLQ.0000000000001063.

Authors

Anna Powell¹, Khalil G Ghanem², Linda Rogers¹, Ashley Zinalabedini¹, Rebecca M Brotman³, Jonathan Zenilman², Susan Tuddenham²

Affiliations

¹ From the Department of Obstetrics and Gynecology.
² Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine.
³ Institute for Genome Sciences, University of Maryland, Baltimore, MD.

Abstract

A retrospective chart review characterized clinicians' use of maintenance intravaginal boric acid for women with recurrent vulvovaginal candidiasis or bacterial vaginosis. Average length of use was 13 months with high patient satisfaction and few adverse events. Prospective studies are needed to evaluate the efficacy of maintenance boric acid for these conditions.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Administration, Intravaginal
Adult
Anti-Infective Agents, Local / administration & dosage*
Boric Acids / administration & dosage*
Candidiasis, Vulvovaginal / drug therapy*
Drug Administration Schedule
Female
Humans
Middle Aged
Patient Satisfaction
Recurrence
Retrospective Studies
Treatment Outcome
Vaginosis, Bacterial / drug therapy*

Substances

Anti-Infective Agents, Local
Boric Acids
boric acid

Grants and funding

K23 AI125715/AI/NIAID NIH HHS/United States